Friday, September 4

Browsing: Ropeginterferon

Treatments

Can Ropeginterferon Elicit Disease Modification in Essential Thrombocythemia?

By NewsCancerSeptember 4, 20260

In August 2026, the FDA approved ropeginterferon alfa-2b-njft (BESREMi) as a second-line therapy for essential thrombocythemia. Approaches combining ropeginterferon alfa…

Survivors

FDA OKs Ropeginterferon Alfa for Essential Thrombocytopenia

By NewsCancerAugust 31, 20260

The FDA has approved ropeginterferon alfa-2b-njft (BESREMi) as a treatment for adult patients with essential thrombocytopenia, according to a press…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

<![CDATA[Conclusions and Award Ceremony]]>

Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Browsing: Ropeginterferon

Can Ropeginterferon Elicit Disease Modification in Essential Thrombocythemia?

FDA OKs Ropeginterferon Alfa for Essential Thrombocytopenia

<![CDATA[Conclusions and Award Ceremony]]>

Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

AI’s Evolving Role in Radiation Oncology

<![CDATA[Conclusions and Award Ceremony]]>

Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

AI’s Evolving Role in Radiation Oncology

Latest Post

<![CDATA[Conclusions and Award Ceremony]]>

Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Ropeginterferon